Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Delivery: Parenteral Route

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia.

Science (New York, N.Y.)·2025

Same author

Drug Delivery through Co-amorphous Solid Dispersions: A Comprehensive and Updated Review on Physicochemical Characteristics and Biological Potential.

Recent advances in drug delivery and formulation·2025

Same author

Demystifying the Potential of Embelin-Loaded Nanoformulations: a Comprehensive Review.

AAPS PharmSciTech·2024

Same author

Nanocarrier-based Delivery Approaches of Mangiferin: An Updated Review on Leveraging Biopharmaceutical Characteristics of the Bioactive.

Current pharmaceutical biotechnology·2024

Same author

Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review.

AAPS PharmSciTech·2024

Same author

Transfersome, an ultra-deformable lipid-based drug nanocarrier: an updated review with therapeutic applications.

Naunyn-Schmiedeberg's archives of pharmacology·2023

Search research articles

Related Experiment Video

Updated: Apr 4, 2026

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

Published on: August 15, 2019

Solid Lipid Nanoparticle Mediated Intranasal Drug Delivery for Brain Targeting: A Comprehensive Review.

Vaishali Kaushal¹, Abdul Hafeez¹, Shazia Afzal Usmani¹

¹Faculty of Pharmacy, Integral University, Lucknow, 226026, India.

CNS & Neurological Disorders Drug Targets

|April 3, 2026

Summary

Intranasal administration using Solid Lipid Nanoparticles (SLNs) offers a direct, non-invasive pathway to the brain, bypassing the blood-brain barrier (BBB). This approach enhances drug delivery for various brain diseases, showing significant therapeutic potential.

Keywords:

Solid lipid nanoparticles biocompatibility blood-brain barrier brain targeting intranasal drug delivery neurological disorders.

More Related Videos

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Published on: November 14, 2018

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Apr 4, 2026

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

Published on: August 15, 2019

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Published on: November 14, 2018

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Area of Science:

Neuroscience
Nanotechnology
Pharmacology

Background:

The blood-brain barrier (BBB) limits drug efficacy for central nervous system disorders.
Intranasal drug delivery offers a non-invasive route for direct brain targeting.
Nasal cavity anatomy facilitates drug transport via olfactory and trigeminal nerves, bypassing the BBB.

Purpose of the Study:

To review the potential of Solid Lipid Nanoparticles (SLNs) for intranasal drug delivery to the brain.
To explore the efficacy of intranasally delivered SLNs for treating various brain diseases.
To summarize in vitro and in vivo findings on SLN-based intranasal brain targeting.

Main Methods:

Literature review of studies on intranasal SLNs for brain diseases.
Analysis of SLN characteristics (size, composition) for brain delivery.
Evaluation of in vitro and in vivo data on drug-loaded SLNs administered intranasally.

Main Results:

Solid Lipid Nanoparticles (SLNs) are biocompatible drug delivery systems with controlled release and enhanced bioavailability.
Intranasal SLNs demonstrated high brain targeting potential for various neurological conditions.
The size of effective drug-loaded SLNs for intranasal brain delivery ranged from 65-210 nm.

Conclusions:

Intranasal SLNs represent a promising strategy for overcoming BBB limitations in treating brain diseases.
Further research and clinical trials support the development of SLNs for effective brain disease management.
This delivery platform holds significant potential for improving therapeutic outcomes in neurology.